0 results available. Select is focused ,type to refine list, press Down to open the menu,
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The compan...
We've identified the following companies as similar to Inozyme Pharma Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Fair Value Upside represents the discount (if positive) or premium (if negative) implied by a company’s current stock price when compared to our estimate of intrinsic value. It is the inverse of Fair Value Downside
Upside = (Fair Value Estimate / Stock Price - 1)
The chart above depicts the distribution of fair value upside (finbox) for companies operating in the Healthcare sector in the Developed economic region. Over 2,330 companies were considered in this analysis, and 2,240 had meaningful values. The average fair value upside (finbox) of companies in the sector is 9.6% with a standard deviation of 24.2%.
Inozyme Pharma Inc's Fair Value Upside (FINBOX) of 59.0% ranks in the 98.9% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,334 |
| Included Constituents | 2,240 |
| Min | -49.6% |
| Max | 62.3% |
| Median | 10.4% |
| Mean | 9.6% |
| Standard Deviation | 24.2% |
You can find companies with similar fair value upside (finbox) using this stock screener.